IsoPlexis Corporation (ISO)

NASDAQ: ISO · IEX Real-Time Price · USD
1.35
0.00 (0.00%)
Dec 2, 2022 4:30 PM EST - Market closed
Market Cap 57.75M
Revenue (ttm) 18.94M
Net Income (ttm) -98.49M
Shares Out 39.46M
EPS (ttm) 9.29
PE Ratio 0.15
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,697
Open 1.42
Previous Close 1.35
Day's Range 1.34 - 1.49
52-Week Range 1.33 - 11.25
Beta n/a
Analysts Buy
Price Target 3.40 (+151.9%)
Earnings Date Nov 10, 2022

About ISO

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provide... [Read more]

Industry Medical Devices
IPO Date Oct 8, 2021
Employees 459
Stock Exchange NASDAQ
Ticker Symbol ISO
Full Company Profile

Financial Performance

In 2021, IsoPlexis's revenue was $17.26 million, an increase of 66.15% compared to the previous year's $10.39 million. Losses were -$81.57 million, 250.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ISO stock is "Buy." The 12-month stock price forecast is 3.4, which is an increase of 151.85% from the latest price.

Price Target
$3.4
(151.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IsoPlexis Reports Third Quarter 2022 Financial Results

BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported f...

3 weeks ago - GlobeNewsWire

IsoPlexis to Participate in Upcoming Investor Conferences

BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced ...

3 weeks ago - GlobeNewsWire

IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced ...

1 month ago - GlobeNewsWire

IsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform

BRANFORD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, t...

2 months ago - GlobeNewsWire

IsoPlexis Partners with MediMergent and The Center for Cancer and Blood Disorders in Study of AZD7442 for Prevention ...

Large multi-site COVID-19 study to use IsoPlexis Single Cell Functional Proteomics to survey immunity. Large multi-site COVID-19 study to use IsoPlexis Single Cell Functional Proteomics to survey immunity.

2 months ago - GlobeNewsWire

IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference

BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, to...

3 months ago - GlobeNewsWire

IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum “Homi” Shamir to its Board...

BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, to...

3 months ago - GlobeNewsWire

IsoPlexis Reports Second Quarter 2022 Financial Results

BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported f...

3 months ago - GlobeNewsWire

IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022

BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before m...

4 months ago - GlobeNewsWire

IsoPlexis Reports First Quarter 2022 Financial Results

First quarter 2022 revenue increased 52% over prior year period First quarter 2022 revenue increased 52% over prior year period

6 months ago - GlobeNewsWire

IsoPlexis Reports Preliminary First Quarter 2022 Revenue, Streamlines Operating Structure to Support Sustainable Growth

Reiterates full year guidance and extends cash runway to H2 2024 Reiterates full year guidance and extends cash runway to H2 2024

7 months ago - GlobeNewsWire

IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Function...

IsoLight and Duomic Technologies Detect T Cell Receptors and Highly Multiplexed Functional Cytokines from the Same Single Cells to Advance Cancer Immunology Discovery IsoLight and Duomic Technologies De...

7 months ago - GlobeNewsWire

IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022

2021 revenue increased 66% over prior year period 2021 revenue increased 66% over prior year period

9 months ago - GlobeNewsWire

IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year...

9 months ago - GlobeNewsWire

IsoPlexis to Participate in Three Upcoming Investor Conferences

BRANFORD, Conn., Feb. 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced the company will be participating in the following investor conferences.

9 months ago - GlobeNewsWire

IsoPlexis' Immune Monitoring Helps Identify Early Factors of Long COVID

IsoPlexis Corporation ISO has announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium. Get the Inside Access Traders Are Using to Profit More ...

9 months ago - Benzinga

IsoPlexis' Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication

Single-cell functional proteomics identifies biological factors and immune cell types that drive Long COVID in convalescent COVID-19 patients Single-cell functional proteomics identifies biological fact...

9 months ago - GlobeNewsWire

IsoPlexis Strengthens International Reach and Leadership with First APAC Office and Jason Ou as President/General Man...

BRANFORD, Conn., Feb. 02, 2022 (GLOBE NEWSWIRE) -- IsoPlexis, the Superhuman Cell Company, today announced the opening of its first office in the Asia-Pacific (APAC) region headed by Jason Ou as Preside...

10 months ago - GlobeNewsWire

IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library

Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrum Superhero cells are key to the efficacy, potency, and durability of therapies across the hu...

10 months ago - GlobeNewsWire

IsoPlexis to Present IsoLight® Single-Cell Proteomics Data at ASH 2021 Conference

BRANFORD, Conn., Dec. 8, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single cell proteomics, today announced that new data generated on its IsoLight® platform will be presente...

11 months ago - PRNewsWire

IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and ...

1 year ago - PRNewsWire

IsoPlexis to Participate in the Evercore ISI HealthCONx Conference

BRANFORD, Conn., Nov. 24, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today announced the company will be participating virtually in the up...

1 year ago - PRNewsWire

IsoPlexis' Expanded Cell Therapy Offerings Demonstrated in Nature Medicine Publications

BRANFORD, Conn., Nov. 18, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the publication of two high-impact clinical research ...

1 year ago - PRNewsWire

IsoPlexis Bolsters Its Global Operational and Product Support Leadership

BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company.

1 year ago - PRNewsWire

IsoPlexis Reports Third Quarter 2021 Financial Results

BRANFORD, Conn., Nov. 10, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, ...

1 year ago - PRNewsWire